Antibodies

02 Jul 2019 Bioinvent Receives Ind Approval For Phase I/IIa Trial of Anti-FcγRIIb Antibody
01 Jul 2019 CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
01 Jul 2019 Menarini Ricerche Announces Publication of Pre-clinical Data of the First-in-class Antibody-drug Conjugate MEN1309/OBT076, Currently in Phase I Clinical Development
01 Jul 2019 Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
01 Jul 2019 Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
28 Jun 2019 CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
28 Jun 2019 Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
28 Jun 2019 New report: Bispecific Antibodies for Immuno-Oncology & Other Diseases
27 Jun 2019 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
27 Jun 2019 IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
27 Jun 2019 NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)
27 Jun 2019 Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes
27 Jun 2019 FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
25 Jun 2019 I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States
24 Jun 2019 Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
24 Jun 2019 Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
24 Jun 2019 Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue® (Trastuzumab Biosimilar)
22 Jun 2019 ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
22 Jun 2019 European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
21 Jun 2019 Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants
21 Jun 2019 Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
19 Jun 2019 Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
19 Jun 2019 Alligator Bioscience Submits Clinical Trial Application for ATOR-1017
19 Jun 2019 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
18 Jun 2019 PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top